COVID-19 clinical trials and the promise of a vaccine

The genome sequence of the SARS-Cov-2 virus was deposited on a National Institutes of Health (NIH) server on Jan. 10, 2020. Within days, scientists all over the world started to use the sequence to make vaccines. Two vaccines are now approved for limited use; eight vaccines are in large-scale phase 3 clinical trials; 13 are in expanded phase 2 safety trials; 21 are moving through phase 1 safety testing. 

More than 135 vaccines are at earlier stages of development. These numbers are being curated by the New York Times and are updated frequently. Search for their Coronavirus Vaccine Tracker; The Times will not fail to keep you updated. 

How the vaccines work

All of the vaccines are designed to present a SARS-CoV-2 spike protein to the human immune system and provoke the production of circulating antibodies and T-cells that kill lung or other cells infected with the virus. After a vaccination or illness, the immune response subsides, but many antibody-producing B cells and cell-killing T cells are banked. When infection occurs, thousands or millions of lymphocytes leap into action and block or minimize the infection. 

With some vaccines the banked cells last a long time; with others, only a few months

The spike protein is a string of about 400 amino acids in a unique order. During its synthesis, the protein folds into a spike shape and is assembled into the SARS-CoV-2. The tip of the spike protein grasps a protruding protein on the surface of human cells and the attached virus is pulled inside, where it unfolds and starts the production of much more virus. 

mRNA as one option

The vaccines in phase 3 testing are all products of genetic manipulation. In one approach, scientists inserted the gene that carries the information for the spike protein into an attenuated animal virus. The Oxford-AstraZeneca group uses a weakened chimpanzee adenovirus with an inserted spike protein gene. They have a Phase III trial in Arizona and lots of other places. The Chinese have four vaccines completing phase 3 and starting general use. 

The method that is most intriguing to me is purely chemical. Recipients get no live or dead virus, which is reassuring for some people. The new method makes the mRNA that provides instructions for the synthesis of the spike protein, but all in a test tube. The scientists wrap the coding mRNA in lipid and inject it into macaques or humans, where it enters cells and uses their protein synthesis capacity to make spike protein. 

In macaques, the mRNA-1273 vaccine successfully defends the host from the coronavirus. This novel vaccine is the product of Tony Fauci’s National Institute of Allergy and Infectious Diseases and a company called Moderna that specializes in RNA-based defenses against infectious disease. The vaccine is in phase 3 trials on 30,000 people. 

Seeking trial volunteers 

The study is recruiting volunteers. 

All clinical trials must register with an organization at the National Library of Medicine at the NIH. Anyone can find the list of clinical trials for a disease or condition at www.ClinicalTrials.gov. If you are interested in joining a SARS-Cov-2 clinical trial, you will also find medical centers involved in the trials at that website  (enter code identifier NCT04470427).

Being a participant requires commitment, because the people running a trial want to know if you produce antibody and new T-cells in response to a vaccination and how long it lasts — which means occasional blood tests. 

They want to know about side effects of inoculation. They are eager to have and are required to have participants of all ages and ethnicities. 

In the Northeast, there are few sites because there is a relatively low level of disease. If we want to test a vaccine, we have to go where disease rates are high—in the United States that means Texas, Alabama, Georgia, Arizona, Missouri and California.

The new techniques now being tested are effective and fast but we have to know about new viruses that will surely appear. New techniques will not do us much good if we ignore pandemic preparedness plans, eliminate virus surveillance programs, leave the World Health Organization, disparage the CDC and denigrate scientists and physicians who are trying to keep us alive. 

 

Richard Kessin Ph.D is Professor Emeritus of Pathology and Cell Biology at Columbia University’s Irving Medical Center. He can be reached at Richard.kessin@gmail.com.

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

Sharon voters reject controversial school budget, 114-99

The May 8 town meeting and budget vote were moved from Sharon Town Hall to Sharon Center School to accommodate what officials said was the largest turnout for a Sharon budget meeting in recent years.

Alec Linden

SHARON – More than 200 residents packed the Sharon Center School gymnasium Friday, May 8, where voters narrowly rejected the Sharon Board of Education's proposed 2026-2027 spending plan by a vote of 114-99, sending the budget back to the Board of Finance after weeks of heated debate over school funding.

The rejected proposal – the ninth version of the budget since deliberations began months ago – carried a bottom line of $4,165,513 for the elementary school, unchanged from last year. The flat budget came after the BOF ordered the BOE in early April to remove nearly $70,000 from its spending plan.

Keep ReadingShow less

Liane McGhee

Liane McGhee
Liane McGhee
Liane McGhee

Liane McGhee, a woman defined by her strength of will, generosity, and unwavering devotion to her family, passed away leaving a legacy of love and cherished memories.

Born Liane Victoria Conklin on May 27, 1957, in Sharon, CT, she grew up on Fish Street in Millerton, a place that remained close to her heart throughout her life. A proud graduate of the Webutuck High School Class of 1975, Liane soon began the most significant chapter of her life when she married Bill McGhee on August 7, 1976. Together, they built a life centered on family and shared values.

Keep ReadingShow less
‘Women Laughing’ celebrates New Yorker cartoonists

Ten New Yorker cartoonists gather around a table in a scene from “Women Laughing.”

Eric Korenman

There is something deceptively simple about a New Yorker cartoon. A few lines, a handful of words — usually fewer than a dozen — and suddenly an entire worldview has been distilled into a single panel.

There is also something delightfully subversive about watching a room full of women sit around a table drawing them. Not necessarily because it seems unusual now — thankfully — but because “Women Laughing,” screening May 9 at The Moviehouse in Millerton, reminds us that for much of The New Yorker’s history, such a gathering would have been nearly impossible to imagine.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

By any other name: becoming Lena Hall

By any other name: becoming Lena Hall

In “Your Friends and Neighbors,” Lena Hall’s character is also a musician.

Courtesy Apple TV
At a certain point you stop asking who people want you to be and start figuring out who you already are.
Lena Hall

There is a moment in conversation with actress and musician Lena Hall when the question of identity lands with unusual force.

“Well,” she said, pausing to consider it, “who am I really?”

Keep ReadingShow less
Remembering Todd Snider at The Colonial Theatre

“A Love Letter to Handsome John” screens at The Colonial Theatre on May 8.

Provided

Fans of the late singer-songwriter Todd Snider will have a rare opportunity to gather in celebration of his life and music when “A Love Letter to Handsome John,” a documentary by Otis Gibbs, screens for one night only at The Colonial Theatre in North Canaan on Friday, May 8.

Presented by Wilder House Berkshires and The Colonial Theatre, the 54-minute film began as a tribute to Snider’s friend and mentor, folk legend John Prine. Instead, following Snider’s death last November at age 59, it became something more intimate: a portrait of the alt-country pioneer during the final year of his life.

Keep ReadingShow less
Sharon Playhouse debuts new logoahead of 2026 season

New Sharon Playhouse logo designed by Christina D’Angelo.

Provided

The Sharon Playhouse has unveiled a new brand identity for its 2026 season, reimagining its logo around the silhouette of the historic barn that has long defined the theater.

Sharon Playhouse leadership — Carl Andress, Megan Flanagan and Michael Baldwin — revealed the new logo and website ahead of the 2026 season. The change reflects leadership’s desire to embrace both the Playhouse’s history and future, capturing its nostalgia while reinventing its image.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.